Adaptimmune

Industry · 14 registered clinical trials.

Status	Trial	Phase	Started
Terminated	ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS- Esophageal Cancer, Esophagogastric Junction Cancer	Phase 2	2021-09-15
Terminated	Study of GSK3901961 In Previously Treated Advanced (Metastatic OR Unresectable) Synovial Sarcoma/ Myxoid/Round Neoplasms	Phase 1	2021-03-09
Terminated	Study of GSK3845097 in Previously Treated Participants With Advanced Synovial Sarcoma and Myxoid/Round Cell Li Neoplasms	Phase 1	2020-12-21
Terminated	Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO- Neoplasms	Phase 1	2020-12-21
Withdrawn	SPEARHEAD 2 Study in Subjects With Recurrent or Metastatic Head and Neck Cancer Head and Neck Cancer	Phase 2	2020-07-02
Terminated	Long Term Follow up of Subjects Exposed to Genetically Engineered T Cell Receptors Solid and Hematological Malignancies	—	2018-02-28
Active Not Recruiting	MAGE-A4ᶜ¹º³²T for Multi-Tumor Urinary Bladder Cancer, Melanoma, Head and Neck Cancer	Phase 1	2017-05-15
Active Not Recruiting	AFPᶜ³³²T in Advanced HCC Hepatocellular Cancer, AFP Expressing Tumors	Phase 1	2017-05-08
Completed	MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers Urothelial Carcinoma, Head and Neck Cancer, Melanoma	Phase 1	2016-10-01
Completed	Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination Solid and Hematological Malignancies	—	2015-12-01
Completed	MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC Non-Small Cell Lung Cancer, Carcinoma	Phase 1	2015-11-01
Terminated	CT Antigen TCR-Engineered T Cells for Myeloma Multiple Myeloma	Phase 1 / Phase 2	2013-10-15
Completed	CT Antigen TCR-redirected T Cells for Ovarian Cancer. Ovarian Cancer	Phase 1 / Phase 2	2013-07-09
Terminated	Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma	Phase 1 / Phase 2	2011-06-01